Первая клетка. И чего стоит борьба с раком до последнего

Fojo T. et al. Unintended Consequences of Expensive Cancer Therapeutics – The Pursuit of Marginal Indications and a Me-Too Mentality That Stifles Innovation and Creativity: The John Conley Lecture. JAMA Otolaryngology – Head & Neck Surgery. 140, no. 12 (2014): 1225–1236.

Marchetti S., Schellens J. H. M. The Impact of FDA and EMEA Guidelines on Drug Development in Relation to Phase 0 Trials. British Journal of Cancer. 97 (2007): 577–581.

Kummar Sh. Compressing Drug Development Timelines in Oncology Using Phase ‘0’ Trials. Nature Reviews Cancer. 7 (2007): 131–139.

Murgo J. A. et al. Designing Phase 0 Cancer Clinical Trials. Clinical Cancer Research. 14, no. 12 (2008).

Spector R. The War on Cancer: A Progress Report for Skeptics. Skeptical Inquirer, January/February 2010.

Hitchens Ch. Topic of Cancer. Vanity Fair, August 2010.

Adams C. P., Brantner V. V. Estimating the Cost of New Drug Development: Is It Really 802 Million Dollars? Health Affairs (Millwood). 25, no. 2 (2006): 420–428.

Глава 5. Джей-Си

Donor Registry Data. US Department of Health and Human Services. https://bloodcell.transplant.hrsa.gov/research/registry_donor_data/index.html

Koutsavlis I. Transfusion Thresholds, Quality of Life, and Current Approaches in Myelodysplastic Syndromes. Anemia, 2016. doi:10.1155/2016/8494738.

Black Bone Marrow.com. http://blackbonemarrow.com/

Poynter J. N. et al. Chemical Exposures and Risk of Acute Myeloid Leukemia and Myelodysplastic Syndromes in a Population-Based Study. International Journal of Cancer. 140, no. 1 (2017): 23–33.

Murphy T., Yee K. W. L. Cytarabine and Daunorubicin for the Treatment of Acute Myeloid Leukemia. Expert Opinion on Pharmacotherapy. 18, no. 16 (2017): 1765–1780.

Steele J. The Man Who Would Tame Cancer: Patrick Soon-Shiong Is Opening a New Front in the War on the Deadly Disease. Nautilus, January 28, 2016.

Raza A. et al. Apoptosis in Bone Marrow Biopsy Samples Involving Stromal and Hematopoietic Cells in 50 Patients with Myelodysplastic Syndromes. Blood. 86, no. 1 (1995): 268–276.

Raza A. et al. Novel Insights into the Biology of Myelodysplastic Syndromes: Excessive Apoptosis and the Role of Cytokines. International Journal of Hematology. 63, no. 4 (1996): 265–278.

Raza A. et al. Thalidomide Produces Transfusion Independence in Long Standing Refractory Anemias of Patients with Myelodysplastic Syndromes. Blood. 98, no. 4 (2001): 958–965.

Raza A., Galili N. The Genetic Basis of Phenotypic Heterogeneity in Myelodysplastic Syndromes. Nature Reviews Cancer. 12, no. 12 (2012): 849–859.

Глава 6. Андрей

Wen P. Y., Kesari S. Malignant Gliomas in Adults. New England Journal of Medicine. 359 (2008): 492–507.

Stewart L. A. Chemotherapy in Adult High-Grade Glioma: A Systematic Review and Meta-Analysis of Individual Patient Data from 12 Randomised Trials. Lancet. 359 (2002): 1011–1018.

KÜbler-Ross E. On Death and Dying. New York: Scribner, 1997.

[Кюблер-Росс Э. О смерти и умирании. СПб: Корвет, 2016.]

Izard J., Siemens D. R. What’s in Your Toolkit? Guiding Our Patients Through Their Shared Decision-Making. Canadian Urological Association Journal. 12, no. 10 (2018): 294–295.

Hagedoorn M. et al. Coping with Cancer: The Perspective of Patients’ Relatives. Acta Oncologica. 50, no. 2 (2011): 205–211.